Phase 1a/1b data presented at ESMO 2026 show a median progression-free survival of 11.4 months in 32 salivary gland cancer patients treated with faridoxorubicin, which Avacta (LSE:AVCT) compares with a historical range of 6 to 6.7 months for existing therapies. The comparison is not from a randomised trial, and no statistical significance is claimed.

What was announced

Avacta Group plc (LSE:AVCT), which trades as Avacta Therapeutics, released updated data on 26 October 2026 from its ongoing phase 1a/1b trial of faridoxorubicin (AVA6000) in salivary gland cancer (SGC). The results were presented as poster 1549P at the European Society for Medical Oncology (ESMO) Congress in Madrid on Monday 26 October, between 12:00 and 12:45pm CET. Alan L. Ho was the senior author; the release notes that he has financial interests related to Avacta.

Faridoxorubicin is Avacta's first-generation pre|CISION peptide-drug conjugate. It is a form of the chemotherapy doxorubicin designed to be released by fibroblast activation protein (FAP), an enzyme found in the tumour microenvironment, so that the active drug is concentrated in tumour tissue.

The phase 1a stage was a dose escalation in patients with cancers that are frequently FAP-positive. The phase 1b expansion covers SGC, soft tissue sarcoma and triple-negative breast cancer; data in the latter two indications are still maturing.

The numbers

Across all doses and cohorts, 51 SGC patients with any prior therapy were enrolled. The efficacy analysis focused on 32 SGC patients treated at doses of 310 mg/m² and above, given every three weeks or every two weeks. Patients with rare histologies or more extensive prior therapy were excluded from this analysis. The data cut-off was 5 October 2026.

In this group, median progression-free survival (PFS) was 11.4 months (95% CI 7 months to not reached). Avacta compares this with a historical benchmark of 6 to 6.7 months for first- and second-line cytotoxic chemotherapy and targeted therapy, citing Kanno et al. 2025, and describes the result as nearly two-fold. The benchmark is drawn from published literature rather than a control arm within the trial, and the release does not claim statistical significance. Median overall survival had not been reached.

There were three partial responses and six minor responses, with response durations ranging from 18.7 to 72 weeks. The release does not give an objective response rate or disease control rate. Faridoxorubicin was described as "well-tolerated" in this SGC group, but no specific adverse event rates or cardiac safety data were reported.

Biopsy data showed a tumour-to-plasma concentration ratio of released doxorubicin of 100:1, with tumour reductions seen even at low FAP expression (1+). FAPI-PET imaging and FAP immunohistochemistry indicated that FAP expression did not diminish during treatment across several tumour types, and plasma pharmacokinetics out to 12 cycles showed stable cleavage of the drug by FAP.

What the company said

Christina Coughlin, Chief Executive Officer of Avacta, said: "This is further evidence that the effect of pre|CISION PDCs can persist even as tumors shrink." Alan Ho, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center in New York, said: "These are promising results with faridoxorubicin in patients with salivary gland cancers."

Separate preclinical data on FAP-Exd (AVA6103), Avacta's lead candidate, were also presented at ESMO. Avacta said they suggest treated tumours recruit new FAP-positive fibroblasts, which enhances cleavage of the payload over time.

What to watch next

Avacta expects tumour pharmacokinetic and cleavage durability data for AVA6103 in late 2026, followed by first efficacy data for AVA6103 in the first half of 2027. The release does not set out phase 2 or registrational plans for faridoxorubicin, and it does not mention the company's cash position or funding. Further results from the sarcoma and breast cancer expansion cohorts are also pending, with no timing given.